Patients with prurigo nodularis-like phenotype atopic dermatitis benefit from talokinumab, according to the JAAD.

Published Date: 07 Jul 2023

Italy: Patients with prurigo nodularis-like phenotype atopic dermatitis showed clinical improvement after receiving talokinumab, an IL-13 monoclonal antibody.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot